F S&P 500
4,975.75 -73.25 (-1.45%) F Dow Jones
37,530.00 -477.00 (-1.26%) F Nasdaq
17,241.00 -306.25 (-1.75%) E-mini Russell 2000 Index Futur
1,925.20 -32.90 (-1.68%) Petróleo
85.50 +2.77 (+3.35%) Oro
2,428.40 +30.40 (+1.27%)
Abeona Therapeutics Inc. (ABEO)
Fuera de horario:
Abeona Therapeutics Inc.
6555 Carnegie Avenue
4th Floor
Cleveland, OH 44103
United States
646 813 4701
https://www.abeonatherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 84
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Vishwas Seshadri M.B.A., Ph.D. | President, CEO & Director | 1.49M | N/D | 1977 |
| Mr. Joseph Walter Vazzano CPA | Chief Financial Officer | 920.85k | N/D | 1985 |
| Dr. Brendan M. O'Malley J.D., Ph.D. | Senior VP & General Counsel | 802.95k | N/D | 1970 |
| Mr. Brian Kevany Ph.D. | Senior VP, CTO & CSO | N/D | N/D | N/D |
| Mr. Gregory Gin | Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Ms. Alison Hardgrove | Vice President of Human Resources | N/D | N/D | N/D |
| Mr. Jon Voss | VP & Head of Quality | N/D | N/D | 1960 |
| Mr. Dmitriy Grachev M.D., Ph.D. | Chief Medical Officer | N/D | N/D | N/D |
| Dr. Madhav Vasanthavada M.B.A., Ph.D. | Senior VP, Chief Commercial Officer & Head of Business Development | N/D | N/D | N/D |
| Mr. Carl Denny | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
Descripción
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Gestión corporativa
La calificación ISS Governance QuickScore de Abeona Therapeutics Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
